RxDoctor Payments Data

Steven Diamond, DO

Psychiatry · Garden City, NYNPI 1245272293

Payments from drug & device makers

$15,726in general payments, 2019–2025

Across 960 payments — averaging $16.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$2K
  • AbbVie$2K
  • Lundbeck LLC$2K
  • Neos Therapeutics, LP$2K
  • Takeda Pharmaceuticals U.S.A., Inc.$1K
  • Alkermes, Inc.$1K
  • plus $6K from 22 others

What the payments were for

  • Food & beverage$15,696100%
  • Education$300%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,726 in reported general payments places this provider in the 95th percentile of 3,713 psychiatry providers in New York.

See all psychiatry providers in New York

Medicare billing

Part B allowed, 2024
$99,524
Medicare patients
114
Services billed
1,444

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrintellixVortioxetine Hydrobromide30$19,691
Sertraline Hcl189$2,274
Escitalopram Oxalate273$2,024
Aripiprazole36$1,652
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine46$1,564
Clonazepam305$1,508
Bupropion XlBupropion Hcl77$1,142
Nefazodone Hcl14$1,130
Vilazodone Hcl20$1,070
Alprazolam162$886
Duloxetine Hcl59$810
Venlafaxine Hcl ErVenlafaxine Hcl100$788
Gabapentin31$702
Fluoxetine Hcl99$676
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine12$555

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$1,349$19,69130 claims
Almatica Pharma LLCSertraline Hcl$319$2,274189 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,713 psychiatry providers in New York.

Other psychiatry in Garden City

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →